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ABSTRACT
Poly (ADP-ribose) polymerases (PARPs) are enzymes that transfer ADP-ribose 
groups to target proteins and are involved in a variety of biological processes. PARP6 
is a novel member, and our previous findings suggest that PARP6 may act as a tumor 
suppressor via suppressing cell cycle progression. However, it is still unclear that 
PARP6 function besides growth suppression in colorectal cancer (CRC). In this study, 
we examined tumor suppressive roles of PAPR6 in CRC cells both in vitro and in vivo. 
We found that PARP6 inhibited colony formation, invasion and migration as well 
as cell proliferation. Moreover, ectopic overexpression of PARP6 decreased Survivin 
expression, which acts as an oncogene and is involved in apoptosis and mitosis. 
We confirmed the inverse correlation between PARP6 and Survivin expression in 
CRC cases by immunohistochemistry. Importantly, CRC cases with downregulation of 
PARP6 and upregulation of Survivin showed poor prognosis. In summary, PARP6 acts 
as a tumor suppressor via downregulating Survivin expression in CRC. PARP6 can be 
a novel diagnostic and therapeutic target together with Survivin for CRC.
INTRODUCTION
It is well accepted that colorectal cancer (CRC) is 
the third most common type of cancer and a major cause of 
cancer-related mortality worldwide [1, 2]. At the same time, 
this global public health problem places a major economic 
burden on the global health care system, particularly 
in developing regions. Thus, there is an increased need 
for early diagnosis, drug response predictions and other 
clinical applications associated with CRC.
The presence of Poly (ADP-ribosyl) ation activity 
was originally suggested in the 1960s [3, 4]. PARPs are 
multifunctional nuclear proteases that mediate post-
translational protein modification in the process of poly-
ADP-glycosylation [5, 6]. Post-translational modification 
of proteins by poly (ADP-ribosyl) ation is involved in 
a variety of biological process including DNA repair, 
chromatin structural regulation, gene transcription, cell 
cycle progression and cell death [5, 6]. At present, 17 
members of the PARP family have been identified, such 
as PARP1-4, 5α, 5β and 6-16 [7, 8]. Moreover, the PARP 
family is correlated with the development of various 
diseases [9, 10]. Among the PARPs, PARP-1, which 
produces polymers of ADP-ribose (PAR) using NAD+ 
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as a substrate, is well studied. PARP-1 promotes tumor 
angiogenesis [7, 11, 12], and elevated expression of 
PARP-1 is found in various cancers including breast [13], 
prostate [14], pancreatic [15] and gastric cancer [16].
PARP6, a new member of the PARP family, is located 
on chromosome 15q23. PARP6 contains the catalytic 
domain of PARP with a considerably shorter nicotinamide-
ribose-binding site than PARP1 and belongs to the mono 
(ADP-ribosyl) transferase class [11, 12, 17]. We previously 
showed that ectopic overexpresssion of PARP6 in HeLa 
cells induced growth suppression in vitro [17]. Moreover, 
PARP6 positivity negatively correlated with the Ki-67 
proliferation index and better prognosis in CRC [17]. 
Our previous findings suggest that PARP6 may act as a 
tumor suppressor via suppressing cell cycle progression. 
However, it is still unclear that PARP6 function besides 
growth suppression in the development of CRC.
Survivin is a member of the inhibitor of apoptosis 
protein (IAP) family, which participates in the inhibition 
of apoptosis, and its overexpression is associated with a 
poor outcome in a variety of human cancers [18–20]. We 
have previously shown that Survivin overexpression is 
correlated with malignant behavior of CRC, hepatocellular 
carcinoma and oral squamous cell carcinoma [21–26]. 
Moreover, we found possible correlation between 
Survivin and cell proliferation activity in these cancers. 
Supportively, besides inhibition of apoptosis, Survivin 
regulates chromosome segregation and cytokinesis as 
a chromosomal passenger protein (CPC) that forms a 
complex with Aurora-B, INCENP and Borealin [27, 28].
Here we examined PARP6 expression and its 
correlation with Survivin in a large number of CRC cases. 
Moreover, we examined the tumor suppressive function of 
PARP6 in CRC cells both in vitro and in vivo.
RESULTS
PARP6 inhibits cell proliferation and promotes 
apoptosis in CRC cells
To know the tumor suppressive roles of PAPR6 in 
CRC cells, we used a full-length PARP6 (FL-PARP6) and 
C-terminal deletion mutant PARP6 (ΔC-PARP6). FL-
PARP6 consists of 630 amino acids and the C-terminal 
region (residues 394–620) contains the PARP catalytic 
domain (Figure 1A). ΔC-PARP6 lacks the critical structure 
of the PARP catalytic domain. The SW480 cells were 
transfected with the empty, FL-PARP6 and ΔC-PARP6 
vectors. FFL-PARP6, but not ΔC-PARP6 and control 
inhibited cell growth (Figure 1B). Moreover, FL-PARP6 
significantly reduced the colony formation activity of 
SW480 cells, in comparison with control and ΔC-PARP6 
(Figure 1C). We examined the expression of cell cycle 
related proteins including Survivin, Cyclin B, Aurora-B, 
p21 and p27. Interestingly, ectopic overexpression 
of FL-PARP6 decreased the expression of Survivin, 
Cyclin B and Aurora-B and increased the expression 
of p21 and p27, indicating that PARP6 inhibited cell 
growth via suppressing cell cycle progression (Figure 
1D). Overexpression of ΔC-PARP6 had no effect on the 
expression of these proteins (Figure 1D).
Survivin is a CPC protein and controls chromosome 
segregation and cytokinesis [27]. In addition, Survivin 
is well known as a member of the inhibitor of 
apoptosis protein (IAP) family [18]. Here we found the 
downregulation of Survivin by overexpression of FL-
PARP6 (Figure 1D). Moreover, we observed dead cells 
after overexpression of FL-PARP6 in CRC cells (data not 
shown). Indeed, we observed accumulation of cleaved 
Caspase-3 protein in FL-PARP6 transfectant cells, but 
not in ΔC-PARP6 and empty vector transfectant cells 
(Figure 1E). Moreover, we examined the expression of 
apoptosis related proteins including Bax, Bcl-2 and Bcl-
XL in PARP6 transfectant CRC cells. We observed that 
decreased expression of apoptosis-promoting protein 
(Bax) and increased expression of apoptosis-inhibiting 
proteins (Bcl-2 and Bcl-XL) were observed in FL-PARP6 
transfectant cells, but not ΔC-PARP6 and empty vector 
transfectant cells (Figure 1E).
PARP6 inhibits migration and invasion of CRC 
cells
Next, we examined the effect of ectopic 
overexpression of PARP6 in CRC cells on migration and 
invasion by wound healing assay and in vitro invasion 
assay, respectively. CRC cells expressing FL-PARP6 
exhibited a significantly larger wound area compared to 
ΔC-PARP6 or empty vector transfectant cells (Figure 2A). 
FL-PARP6 dramatically inhibited cell invasion, while 
ΔC-PARP6 and empty vector showed a greater degree of 
invasion (Figure 2B).
We examined the activity of Akt and ERK, which 
are correlated with cell growth, migration, invasion and 
apoptosis. As shown in Figure 2C, the levels of phospho-
Akt and phospho-ERK were significantly decreased in 
FL-PARP6 overexpressing CRC cells. However, ΔC-
PARP6 overexpression had no effect on the expression 
of phospho-Akt and phospho-ERK. These findings 
suggest that tumor suppressive function of PARP6 may be 
mediated by Akt and/or ERK signaling pathway in CRC.
PARP6 inhibits tumor growth in vivo
We examined the tumor suppressive role of PARP6 
in vivo. We subcutaneously transplanted FL-PARP6 or 
empty vector transfected CRC cells into the right groin 
area of the nude mice. After 28 days of transplantation, the 
tumors in FL-PARP6 transfectant group were consistently 
smaller than those in empty vector transfectant group 
(Figure 3A and 3B). Moreover, the sizes and weights 
of the tumors at 28 days after transplantation were 
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significantly lower in FL-PARP6 transfectant group, in 
comparison with empty vector transfectant group (Figure 
3C). We confirmed that high levels of PARP6 expression 
was observed only in FL-PARP6 transfectant group, but 
not in empty vector transfectant group (Figure 3D).
PARP6 expression is inversely correlated with 
the Ki-67 and Survivin in CRC
We examined PARP6 expression and its correlation 
with clinico-pathological findings and proliferation 
Figure 1: PARP6 inhibits cell growth and colony formation. A. A schematic illustration of the human PARP6 protein. PARP6 
consists of 630 amino acid residues and has a PARP catalytic domain in C-terminal region. ΔC-PARP6 lacks the PARP catalytic domain. B. 
Cell proliferation after FL-PARP6 and ΔC-PARP6 overexpression in SW480 cells was measured by MTT assays. After transfection with the 
p-EGFP-empty, p-EGFP-FL-PARP6 or p-EGFP-ΔC-PARP6 plasmids, transfectant cells (1500 cells /well) were replated in 96-well plates. 
The MTT assay was performed to test the cell viability at 24 h, 48 h and 72 h. Values indicate mean ± SD (n=6). C. Colony formation aof 
FL-PARP6 and ΔC-PARP6 transfectant SW480 cells. Cells were plated in 6 cm dishes at a density of 500 cells per dish. After 2 weeks, 
number of colonies were counted. The data represent the means ± S.D. of three independent experiments **P < 0.01. D. Expression of cell 
cycle related proteins including Survivin, Cyclin B, Aurora-B, p21 and p27 in empty vector, FL-PARP6 and ΔC-PARP6 transfectant SW480 
cells was examined by Western blot analysis. β-actin expression was used as a loading control. E. Expression of apoptosis related proteins 
including cleaved Caspase-3, Caspase-3, Bax, Bcl-2 and Bcl-XL in empty vector, FL-PARP6 and ΔC-PARP6 transfectant SW480 cells was 
examined by Western blot analysis. β-actin expression was used as a loading control.
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marker, Ki-67 in 20 normal colonic mucosa and 238 CRC 
samples by immunohistochemistry. Cytoplasmic PARP6 
exhibited strong staining in all normal colonic mucosa, but 
116 of 238 (48.7%) CRC cases exhibited high expression 
of PARP6 in the cytoplasm (Figure 4A and Table 1). We 
observed that the PARP6-positive cells were particularly 
observed in the cytoplasm of well differentiated 
adenocarcinoma, but not in poorly differentiated 
adenocarcinoma (Figure 4A). Low expression of 
PARP6 was significantly correlated with malignant 
behaviors including lymph node metastasis, histological 
differentiation and tumor staging (Table 1). Ki-67 was 
more frequently expressed in poorly differentiated 
adenocarcinoma (Figure 4A). Among 238 CRC cases, 
Ki-67 positivity was higher in PARP6-negative cases, in 
comparison with PARP6-positive cases (Figure 4B).
In this study, we found downregulation of Survivin 
in FL-PARP6 overexpressing CRC cells. Moreover, 
we previously found that Survivin overexpression 
is correlated with malignant behavior including cell 
proliferation activity in CRC [23, 25, 26]. Therefore, 
we examined the correlation between PARP6 and 
Figure 2: PARP6 inhibits invasion and migration. A. Empty vector, FL-PARP6 and ΔC-PARP6 transfectant cells were subjected to 
wound healing assays. The uncovered areas as a percentage of the original wound area were quantified. **, P < 0.01 is based on the Student 
t test. All results were from three independent experiments. Error bars, SD. B. Empty vector, FL-PARP6 and ΔC-PARP6 transfectant cells 
were subjected to in vitro invasion assays using matrigel. Number of cells that invaded through matrigel was counted. We performed the 
assay 3 times and 5 randomly selected fields from each membrane were counted under a light microscope at x100 magnification. **, P< 
0.01 is based on the Student t test. Error bars, SD. C. Expression of phospho- and total protein of Akt and ERK in empty vector, FL-PARP6 
and ΔC-PARP6 transfectant SW480 cells by Western blot analysis. β-actin expression was used as a loading control.
Oncotarget18816www.impactjournals.com/oncotarget
Survivin in the serial sections from the same CRC cases 
by immunohistochemical analysis. In 238 CRC cases, 
high expression of Survivin was observed in 87 (36.5%) 
cases (Table 1). As expected, Survivin expression was 
significantly correlated with malignant behaviors including 
lymph node metastasis, histological differentiation and 
tumor staging (Table 1). High expression of Survivin was 
observed in both nucleus and cytoplasm of CRC cells, but 
Survivin expression was not observed in normal colonic 
mucosa cases (Figure 4A and Table 1). The expression 
patterns of the Ki-67 and Survivin appeared to be similar in 
CRC cases (Figure 4A). The frequency of Ki-67-positive 
cells was higher in the Survivin-positive cases than in 
the Survivin-negative cases (Figure 4C). Interestingly, 
PARP6 expression was inversely correlated with Survivin 
expression in CRC cases (Figure 4A and Table 2).
We compared the expression pattern of PARP6 
and Survivin with clinico-pathological findings in CRC 
cases. CRC cases with high expression of PARP6 and 
low expression of Survivin significantly decreased the 
lymph node metastasis, histological differentiation and 
delayed tumor progression (Table 3). On the other hand, 
CRC cases with low expression of PARP6 and high 
expression of Survivin significantly increased lymph 
node metastasis, histological differentiation and promoted 
tumor progression (Table 3).
To confirm the inverse correlation between PARP6 
and Survivin, we examined the expression of PARP6 and 
Survivin in 4 cases of CRC tissues and normal adjacent 
colorectal tissues by Western blotting. The expression 
levels of the PARP6 protein in the normal adjacent colon 
tissues were higher than those in the CRC tissues (Figure 
Figure 3: PARP6 inhibits tumor formation in vivo. A. Empty vector and FL-PARP6 transfectant cells were subcutaneously 
inoculated into the lower right flank of the nude mice. B. Representative images of empty vector and FL-PARP6 transfectant tumors 
following subcutaneous injection. C. The tumor volume was calculated using the following formula: tumor volume (mm3) =0.5 × length 
(mm) × width2 (mm2). The tumor weight was measured. Left graph shows tumor volume, and right graph shows tumor weight in empty 
vector and FL-PARP6 transfectant tumors. **P < 0.01. D. Expression of PARP6 protein in empty vector and FL-PARP6 transfectant tumors 
was examined by immunohistochemistry.
Oncotarget18817www.impactjournals.com/oncotarget
4D). However, Survivin displayed an opposite expression 
pattern in the CRC and adjacent colon tissues (Figure 4D).
Survival analysis
To examine the survival rate of 145 CRC patients 
with high or low expression of PARP6 and/or Survivin, 
we used the Kaplan-Meier analysis. The 5-year survival 
rate of the CRC cases with high PARP6 expression 
was significantly higher than those with low expression 
(Figure 5A). However, the CRC cases with high Survivin 
expression had a lower 5-year survival rate compared to 
the cases with low Survivin expression cases (Figure 5A). 
Moreover, the 5-year survival rate of CRC cases with both 
Figure 4: Correlation between PARP6 and Survivin expression in CRC. A. Expression of PAPR6 and Survivin in 238 CRC 
cases was examined by immunohistochemistry. Representative images of PARP6, Ki-67 and Survivin in normal colonic mucosa, well 
differentiated adenocarcinoma and poorly differentiated adenocarcinoma cases. B. Correlation between PARP6 and proliferation marker, 
Ki-67 in CRC cases by immunohistochemistry. Graph shows Ki-67 index in CRC cases with low or high expression of PARP6. C. 
Correlation between PARP6 and Survivin in CRC cases by immunohistochemistry. Graph shows Ki-67 index in CRC cases with low or 
high expression of Survivin. D. The expression of PAPR6 and Survivin were determined in 4 CRC tissues and normal adjacent colorectal 
tissues by Western blot analysis. β-actin was used as a loading control.
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high PARP6 expression and low Survivin expression is 
the highest among the CRC cases with different pattern of 
PARP6 and Survivin expression (Figure 5B). On the other 
hand, CRC cases with low expression of PARP6 and high 
expression of Survivin showed the lowest 5-year survival 
rate (Figure 5B).
DISCUSSION
PARPs are DNA-dependent nuclear enzymes that 
alter protein-protein and protein-DNA interactions by 
transferring negatively charged ADP-ribose moieties from 




PARP6 expression  Survivin expression
Low High p-value Low High p-value
Normal colonic 
mucosa 20 0   0 20  
Colorectal cancer 122 116   151 87  
Age (years)        
 ≧50 110 111   142 79
 
 <50 12 5   9 8
Sex        




 Female 52 46  57 41
Tumor size (mm)        




 <50 71 68  91 48
Histological 
differentiation        




 W/M 80 110  130 60
Lymph node 
metastasis        




 Positive 72 41  52 61
Lymphatic 
invasion        




 Positive 112 100  130 82
Venous invasion        




 Positive 94 87  109 72
Tumor stage        




 D 40 10  16 34
Oncotarget18819www.impactjournals.com/oncotarget
Table 2: Correlation between PARP6 and Survivin expression in CRC
 PARP6 expression Total P-value
Low High
Survivin expression     
 Low 61 90 151
<0.01
 High 61 26 87
 Total 122 116   













Total 61 26 61 90
Age (years)      
 ≧50 54 25 56 86
 
 <50 7 1 5 4
Sex      
 Male 30 16 40 54
 
 Female 31 10 21 36
Tumor size (mm)      
 ≧50 24 15 27 33
 
 <50 37 11 34 58
Histological 
differentiation      
 Por/Muc 25 2 17 4
<0.01
 W/M 36 24 44 86
Lymph node 
metastasis      
 Negative 15 11 35 64
<0.01
 Positive 46 15 26 26
Lymphatic invasion      
 Negative 3 2 7 14
 
 Positive 58 24 54 76
Venous invasion      
 Negative 9 6 19 23
 
 Positive 52 20 42 67
Tumor stage      
 BC 34 19 48 87
<0.01
 D 27 7 13 3
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cellular nicotinamide-adenine-dinucleotide (NAD) to a 
variety of protein substrates [7, 12, 29]. So far, 17 members 
of the PARP family have been identified, and the PARP 
family is involved in the development of various diseases 
including cancer [9, 10].PARP6 is a new member of the 
PARP family, and the roles and underlying mechanisms 
of PARP6 in CRC remain unknown. In this study, we 
demonstrated that PARP6 has key roles in suppressing 
Figure 5: The prognostic value of PAPR6 and Survivin in CRC cases. Kaplan–Meier curves with a univariate analysis (log-
rank) for colorectal cancer according to the expression of PAPR6 and Survivin. A. Left graph shows Kaplan–Meier curves for colorectal 
cancer according to the expression of PAPR6. The prognosis for patients with high PAPR6 expression (n=66) was better than the prognosis 
for patients with low PAPR6 expression (n=79) (P<0.001). Right graph shows Kaplan–Meier curves for colorectal cancer according to the 
expression of Survivin. The prognosis for patients with high Survivin expression (n=49) was poorer than the prognosis for patients with 
low Survivin expression (n=96) (P<0.001). B. The survival analysis of the simultaneous expression of PARP6 and Survivin. The prognosis 
for patients with both high PARP6 expression and low Survivin expression is the best (n=54), and the patients with the worst prognosis 
exhibited both low PARP6 expression and high Survivin expression (n=37). The prognoses of the other two groups were in the middle 
(n=54) (P<0.001). C. Schematic model of the role of PARP6 in CRC progression.
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CRC progression both in vitro and in vivo. Indeed, 
reduced expression of PARP6 protein was observed in 
CRC tissues, in comparison with normal adjacent colon 
tissues by immunohistochemical analysis and Western blot 
analysis. Supportively, mRNA level of PARP6 in CRC 
tissues was much lower than that in normal colon tissues 
by microarray analysis using Oncomine™ (data not 
shown). Importantly, CRC cases with PARP6 expression 
showed better prognosis. Recently, it has been shown that 
hypermethylation of PARP6 was found in hepatoblastoma 
and was well correlated with poor prognosis (Meeting 
abstract in Nihon Geka Gakkai Zasshi 115, p308, 2014 [in 
Japanese]). Therefore, we suggest that downregulation of 
PARP6 in CRC may be caused by hypermethylation of its 
promoter region (Figure 5C).
Survivin is known as a bifunctional protein involved 
in suppression of apoptosis and mitosis. It is well know 
that high expression of Survivin is widely observed 
in various human cancers and associated with a poor 
outcome [30–32]. Moreover, Survivin overexpression 
is associated with a poor outcome in CRC patients [23, 
25, 26]. Interestingly, we found that PARP6 expression 
was negatively correlated with Survivin expression in 
CRC cases and tissues. Moreover, ectopic overexpression 
of PARP6 downregulated Survivin proteinin CRC cells. 
Importantly, CRC cases with both low expression of 
PARP6 and high expression of Survivin showed poor 
prognosis among the CRC cases with different pattern of 
PARP6 and Survivin expression. Although the mechanism 
of downregulation of Survivin by PARP6 is still unclear, 
our findings suggest that the PARP6 expression in 
combination with Survivin expression can be useful for 
prognostic marker in CRC patients.
Here we demonstrated that the PARP6 inhibited cell 
proliferation, colony formation, invasion and migration, 
and promotes apoptosis via its catalytic domain in 
C-terminus in CRC cells. Interestingly, ectopic expression 
of PARP6 decreased the expression of Survivin, Cyclin 
B, Aurora-B, Bcl-2, Bcl-XL and increased the expression 
of p21, p27 and Bax. Moreover, ectopic PARP6 
overexpression inhibited the Akt and ERK signaling 
pathways. Although it is unclear whether alteration of 
these proteins is induced by PARP6 in a direct or indirect 
manner, catalytic domain in C-terminus of PARP6 is 
essential for this phenomenon. ERK and Akt signaling 
pathways are upstream of the regulation of cell cycle 
and apoptosis. Therefore, to know the tumor suppressive 
function of PARP6, the mechanism of suppression of ERK 
and Akt activity by PARP6 are required to be clarified.
In conclusion, we found that PARP6 has tumor 
suppressive roles in CRC via inhibition of cell growth, 
migration and invasion and promotion of apoptosis (Figure 
5C). We believe that PARP6 may be useful for diagnostic 
marker and therapeutic target in clinical application for 
CRC.
MATERIALS AND METHODS
Cell lines and cell culture
The human CRC cell line, SW480, was purchased 
from American Type Culture Collection (ATCC). The cells 
were cultured in Dulbecco’s Modified Eagle’s medium 
(DMEM) with 10% fetal bovine serum (FBS), penicillin 
(50 U/ml) and streptomycin (50 g/ml) and maintained at 
37°C in a humidified atmosphere of 5% CO2.
Plasmid construction and transfection
A full-length cDNA clone encoding PARP6 and 
C-terminal deletion mutant (deletion of 436-630 amino 
acid residues) PARP6 were subcloned into a pEGFP 
vector (pEGFP-FL-PARP6 and pEGFP-ΔC-PARP6). The 
pEGFP-FL-PARP6 plasmid, pEGFP-ΔC-PARP6 plasmid 
or the empty vector was introduced into the SW480 
cells using Lipofectamine 2000. The stable clones were 
obtained by G418 selection (500 mg/ml, Gibco) in the 
culture medium for 2 weeks. In this study, we used pool 
stable clones.
MTT assay
A 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl 
tetrazolium (MTT) assay was used to assess cell 
proliferation. The SW480 cells were transfected with 
the p-EGFP-empty, p-EGFP-FL-PARP6 or pEGFP-ΔC-
PARP6 plasmid. After 48 h, the transfected cells (1500 
cells /well) were replated in 96-well plates. The MTT 
assay was performed to test the cell viability at 24 h, 48 h 
and 72 h, and the absorbance was measured at 490 nm on 
microplate reader.
Colony formation assay
The SW480 cells were transfected with the p-EGFP-
empty, p-EGFP-FL-PARP6 or pEGFP-ΔC-PARP6 
plasmid. After 48 h, the transfected cells were plated in 6 
cm dishes at a density of 500 cells per dish and grown in 
complete medium for 2 weeks. When the clone was visible 
with the naked eye, of the culture was terminated, and the 
colonies were fixed for 10 minutes with methanol, stained 
with crystal violet for 15 minutes, and counted under an 
inverted microscope.
Wound healing assay
For the wounding healing experiment, the 
transfected cells were planted in 6-well plates and 
allowed to grow to complete confluence. Next, the 
cells were wounded by scratching the cell monolayer 
with a sterile plastic 200 μl micropipette tip to create a 
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cleared area. Subsequently, the wounded cell layer was 
rinsed with fresh medium to remove the loose cells. 
Then, serum-free medium was added to the well. After 
incubation at 37°C for 24 h, we captured digital phase-
contrast images using an inverted microscope to monitor 
the wound healing process. The time point immediately 
following scratch wounding was set at 100%. Finally, we 
measured the widths of the wounds on the images and 
calculated the mean percentage of the total distances of 
the wound areas.
Cell invasion assay
Invasion assays were performed in 24-well 
Transwell chambers (BD Biosciences, Bedford, MA, 
USA) containing polycarbonate filters with 8 μm pores 
covered with Matrigel (BD Biosciences). The lower 
compartment contained 0.5 ml of 10% fetal bovine serum 
medium. Approximately 1.5×105 transfected cells were 
resuspended in 200 μl of serum-free medium and placed 
in the upper chamber. After incubation for 24 h at 37°C 
in 5% CO2, the non-invaded cells on the upper surface 
were removed with a cotton swab, and the cells that had 
migrated to the lower surface of the membrane were 
fixed with methanol and stained with hematoxylin for 10 
min each. Then, the filters with migrated cells attached 
to the lower surface were washed three times with PBS. 
We performed the assay 3 times and 5 randomly selected 
fields from each membrane were counted under a light 
microscope at x100 magnification.
Western blot analysis
The colon tissue samples and cell line were 
incubated with RIPA buffer on ice before being subjected 
to the Western blot analysis. The protein concentration 
was detected by the Bradford method, with BSA (Sigma-
Aldrich) as the standard. Equal amounts of the cell and 
tissue extracts (40 μg) were subjected to SDS-PAGE and 
transferred to nitrocellulose membranes (Bio-Rad) for 
antibody blotting. The membrane was then blocked and 
incubated with the primary and secondary antibodies. The 
primary antibodies aginst PARP6 (HPA026991, Sigma-
Aldrich), Survivin (NB500-201, Novus Biologicals, 
Littleton, CO), Aurora-B (Transduction Laboratories), 
Cyclin B1 (Cell Signaling technology), Caspase 3 
(Cell Signaling technology), cleaved Caspase-3 (Cell 
Signaling technology), Bcl-2 (Cell Signaling technology), 
Akt (Cell Signaling technology), phospho-Akt (Cell 
Signaling technology), p38 (Cell Signaling technology), 
phospho-p38 (Cell Signaling technology), β-actin (Cell 
Signaling technology), p21 (Santa Cruz Biotechnology), 
p27 (Santa Cruz Biotechnology), Bax (Santa Cruz 
Biotechnology), Bcl-XL (Santa Cruz Biotechnology), 
ERK (Santa Cruz Biotechnology), and phospho-ERK 
(Santa Cruz Biotechnology) were used.
Xenograft
Ten male nude mice (5-6 weeks old) were purchased 
from the Animal Experiment Center of Guilin Medical 
University. All of the animal experiments were approved 
by the Guilin Medical University Animal Care and 
Use Committee. We randomly divided the nude mice 
into two groups; Control group (p-EGFP-empty vector 
transfectant cells) and PARP6 group (p-EGFP-FL-PARP6 
transfectant cells). The stable pool clones of p-EGFP-
empty vector and p-EGFP-FL-PARP6 were collected 
in the logarithmic growth phase. After washing with 
PBS, the cells were suspended in serum-free medium. 
Subsequently, 200 μl of the cell suspension (containing 
2×107 cells) was subcutaneously injected into the right 
groin area of the mice. After the tumors had formed, the 
mice were observed for tumor growth at 7, 14, 21 and 
28 days. The tumor volumes were calculated with the 
following formula: tumor volume (mm3) =0.5 × length 
(mm) × width2 (square mm). After 28 days, the nude mice 
were euthanized. The tumors were excised and weighed to 
record the wet tumor weight.
Patient and tissue samples
The CRC and normal tissues were obtained from 4 
patients who underwent surgery at the affiliated hospital of 
Guilin Medical University. Paraffin-embedded advanced 
CRC specimens from a total of 238 cases (140 males 
and 98 females), including 113 cases with lymph node 
metastasis, were selected from the pathological files of 
Hiroshima University and Guilin University Hospital 
(1990-2012). All samples were obtained after approval by 
the Ethics Committees of Guilin Medical University and 
Hiroshima University. The age of patients ranged from 37 
to 85 years (mean, 62.8 years). Histologically, 190 cases 
were classified as well and moderately differentiated CRC, 
while 48 cases were classified as poorly differentiated 
CRC. The patients’ clinical characteristics, including 
age, sex, tumor size, tumor differentiation, lymph node 
metastasis, vascular invasion and tumor stage, were 
gathered from the patients’ surgical records. Ninety-three 
patients who were lost to follow-up were excluded from 
this study; 145 CRC patients were subjected to a further 
survival analysis. In addition, 20 sample of normal colonic 
mucosa were examined as controls. The tumors from each 
patient were formalin-fixed and cut into parallel 4-5 mm 
sections. Informed consent was obtained from all subjects.
Immunohistochemical staining
The sections were incubated with a polyclonal 
anti-Survivin antibody (NB500-201, Novus Biologicals, 
Littleton, CO, 1:1000) and an anti-PARP6 antibody 
(HPA026991, Sigma-Aldrich, 1:500). In addition, to 
analyze the cell proliferation and correlate it with PARP6 
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and Survivin expression, we examined Ki-67 expression 
using an anti-Ki-67 monoclonal antibody (MIB-1, Dako). 
The sections were incubated with the primary antibodies 
overnight at 4˚C after antigen retrieval by microwave 
treatment in citrate buffer (pH 6.0). The antibodies were 
detected with the streptavidin-biotin peroxidase system 
(Universal LSAB™2 kit, Dako, Kyoto, Japan). The 
immunohistochemistry grade was defined as - to +++ 
according to the number of stained cells and the intensity 
of the reaction in the individual cells. The grades were 
defined as follows: -, the majority of the cells were not 
positive; +, 5-20% of the tumor cells showed weak to 
moderate immunoreactivity; ++, 20-50% of the tumor 
cells showed moderate immunoreactivity; +++, over 50% 
of the tumor cells showed intense immunoreactivity. The 
PARP6- and Survivin-positive cases were graded as ++ 
or +++, and the negative cases were graded as - or +. A 
labeling index of the percentage of Ki-67-positive cells 
was determined by examining at least 1000 tumor cells in 
five representative areas at ×200 magnification.
Statistical analysis
The SPSS software package was used for the 
statistical analyses. The χ2 test was used to compare 
the data between the groups. The survival analysis was 
conducted using the Kaplan-Meier method and the 
survival characteristics and was compared using log-rank 
tests. A P-value <0.05 was required for significance.
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